• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Targeting RNA modification and mitochondrial metabolism cross talk in leukemic stem cells with CDK7 inhibitor TGN-1062.

作者信息

Kang Hyunjun, Zhang Lianjun, Kaadige Mohan R, Valerio Melissa, Hoang Dinh Hoa, Thode Trason, Weston Alexis, Pathak Khyatiben, Nigam Lokesh, Hansen Nathanial P, Lovell Brooke, Shostak Yuriy, Li Wei, Ghoda Lucy, Li Zhuo, Zhang Bin, Chen Jianjun, Pirrotte Patrick, Kuo Ya-Huei, Sharma Sunil, Marcucci Guido, Nguyen Le Xuan Truong

机构信息

Department of Hematologic Malignancies Translational Science, Beckman Research Institute and City of Hope National Medical Center, Duarte, CA.

Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute, Phoenix, AZ.

出版信息

Blood Adv. 2025 Apr 22;9(8):1900-1906. doi: 10.1182/bloodadvances.2024014225.

DOI:10.1182/bloodadvances.2024014225
PMID:39908477
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12008692/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3751/12008692/9a14fb410376/BLOODA_ADV-2024-014225-gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3751/12008692/72ef748959ec/BLOODA_ADV-2024-014225-ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3751/12008692/fd37a7371220/BLOODA_ADV-2024-014225-gr1al.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3751/12008692/9a14fb410376/BLOODA_ADV-2024-014225-gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3751/12008692/72ef748959ec/BLOODA_ADV-2024-014225-ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3751/12008692/fd37a7371220/BLOODA_ADV-2024-014225-gr1al.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3751/12008692/9a14fb410376/BLOODA_ADV-2024-014225-gr2.jpg

相似文献

1
Targeting RNA modification and mitochondrial metabolism cross talk in leukemic stem cells with CDK7 inhibitor TGN-1062.用CDK7抑制剂TGN-1062靶向白血病干细胞中的RNA修饰与线粒体代谢相互作用
Blood Adv. 2025 Apr 22;9(8):1900-1906. doi: 10.1182/bloodadvances.2024014225.
2
Pansarcoma Analysis of Cyclin-Dependent Kinase and Cyclin Outlier Gene Expression Highlights CDK7 as a Potential Therapeutic Target in Chordoma.细胞周期蛋白依赖性激酶和细胞周期蛋白异常基因表达的泛肉瘤分析突出了CDK7作为脊索瘤潜在治疗靶点的作用。
JCO Precis Oncol. 2025 Jul;9:e2500149. doi: 10.1200/PO-25-00149. Epub 2025 Jul 2.
3
In Vivo Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target.体内筛选揭示白血病干细胞中普遍存在的 RNA 结合蛋白依赖性，并鉴定 ELAVL1 为治疗靶点。
Blood Cancer Discov. 2023 May 1;4(3):180-207. doi: 10.1158/2643-3230.BCD-22-0086.
4
Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML.基于CDK7抑制剂的联合疗法对转化为急性髓系白血病的骨髓增殖性肿瘤的临床前疗效。
Blood. 2025 Feb 6;145(6):612-624. doi: 10.1182/blood.2024026388.
5
NRF2 maintains redox balance via ME1 and NRF2 inhibitor synergizes with venetoclax in NPM1-mutated acute myeloid leukemia.NRF2通过ME1维持氧化还原平衡，且NRF2抑制剂与维奈托克在NPM1突变的急性髓系白血病中具有协同作用。
Cancer Metab. 2025 Jun 18;13(1):32. doi: 10.1186/s40170-025-00401-6.
6
Castration-resistant prostate cancer cells are dependent on the high activity of CDK7.去势抵抗性前列腺癌细胞依赖于 CDK7 的高活性。
J Cancer Res Clin Oncol. 2023 Jul;149(8):5255-5263. doi: 10.1007/s00432-022-04475-3. Epub 2022 Nov 18.
7
Nutrient-sensitizing drug repurposing screen identifies lomerizine as a mitochondrial metabolism inhibitor of chronic myeloid leukemia.营养敏化药物再利用筛选发现洛美利嗪是慢性髓系白血病的一种线粒体代谢抑制剂。
Sci Transl Med. 2024 Jun 12;16(751):eadi5336. doi: 10.1126/scitranslmed.adi5336.
8
6-Thioguanine nucleotide levels are associated with infliximab but not adalimumab levels in inflammatory bowel disease patients on combination therapy.在接受联合治疗的炎症性肠病患者中，6-硫鸟嘌呤核苷酸水平与英夫利昔单抗相关，而与阿达木单抗无关。
Intern Med J. 2024 Nov;54(11):1856-1866. doi: 10.1111/imj.16504. Epub 2024 Sep 5.
9
Multi-omics and biochemical reconstitution reveal CDK7-dependent mechanisms controlling RNA polymerase II function at gene 5'- and 3' ends.多组学和生化重组揭示了CDK7依赖性机制在基因5'端和3'端控制RNA聚合酶II的功能。
Cell Rep. 2025 Jul 22;44(7):115904. doi: 10.1016/j.celrep.2025.115904. Epub 2025 Jun 25.
10
Disrupting the RNA polymerase II transcription cycle through CDK7 inhibition ameliorates inflammatory arthritis.通过抑制 CDK7 来打断 RNA 聚合酶 II 转录周期可改善炎症性关节炎。
Sci Transl Med. 2024 Nov 20;16(774):eadq5091. doi: 10.1126/scitranslmed.adq5091.

本文引用的文献

1
METTL protein family: focusing on the occurrence, progression and treatment of cancer.甲基转移酶样蛋白家族：聚焦于癌症的发生、发展及治疗
Biomark Res. 2024 Sep 17;12(1):105. doi: 10.1186/s40364-024-00652-3.
2
OST-01, a natural product from Baccharis coridifolia, targets c-Myc-dependent ribogenesis in acute myeloid leukemia.OST-01是一种来自菊叶酒神菊的天然产物，靶向急性髓系白血病中c-Myc依赖的核糖体生物合成。
Leukemia. 2024 Mar;38(3):657-662. doi: 10.1038/s41375-024-02146-5. Epub 2024 Jan 17.
3
Resistance to energy metabolism - targeted therapy of AML cells residual in the bone marrow microenvironment.
对骨髓微环境中残留的急性髓系白血病细胞能量代谢靶向治疗的耐药性。
Cancer Drug Resist. 2023 Mar 14;6(1):138-150. doi: 10.20517/cdr.2022.133. eCollection 2023.
4
Mitochondrial fusion is a therapeutic vulnerability of acute myeloid leukemia.线粒体融合是急性髓系白血病的治疗靶点。
Leukemia. 2023 Apr;37(4):765-775. doi: 10.1038/s41375-023-01835-x. Epub 2023 Feb 4.
5
The Role of the mA RNA Methyltransferase METTL16 in Gene Expression and SAM Homeostasis.m6A 甲基转移酶 METTL16 在基因表达和 SAM 稳态中的作用。
Genes (Basel). 2022 Dec 8;13(12):2312. doi: 10.3390/genes13122312.
6
Targeting miR-126 in inv(16) acute myeloid leukemia inhibits leukemia development and leukemia stem cell maintenance.靶向 inv(16) 急性髓系白血病中的 miR-126 抑制白血病发生和白血病干细胞维持。
Nat Commun. 2021 Oct 22;12(1):6154. doi: 10.1038/s41467-021-26420-7.
7
Super-enhancer landscape reveals leukemia stem cell reliance on X-box binding protein 1 as a therapeutic vulnerability.超级增强子景观揭示了白血病干细胞对 X 盒结合蛋白 1 的依赖性，这是一种治疗上的脆弱性。
Sci Transl Med. 2021 Sep 22;13(612):eabh3462. doi: 10.1126/scitranslmed.abh3462.
8
METTL3‑mediated m6A modification of Bcl‑2 mRNA promotes non‑small cell lung cancer progression.METTL3 介导的 Bcl-2 mRNA m6A 修饰促进非小细胞肺癌进展。
Oncol Rep. 2021 Aug;46(2). doi: 10.3892/or.2021.8114. Epub 2021 Jun 16.
9
Escape From Treatment; the Different Faces of Leukemic Stem Cells and Therapy Resistance in Acute Myeloid Leukemia.逃避治疗：急性髓系白血病中白血病干细胞的不同面貌与治疗抗性
Front Oncol. 2021 May 3;11:659253. doi: 10.3389/fonc.2021.659253. eCollection 2021.
10
MYC promotes cancer progression by modulating m A modifications to suppress target gene translation.MYC 通过调节 mA 修饰来抑制靶基因翻译从而促进癌症进展。
EMBO Rep. 2021 Mar 3;22(3):e51519. doi: 10.15252/embr.202051519. Epub 2021 Jan 11.